Skip to content
6-K

Foreign Interim / Material

CELLYAN BIOTECHNOLOGY CO., LTD HKPD

0001213900-26-030790

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2026 · Sep 30, 2025 11M sh
Shares Diluted Q2 2026 · Sep 30, 2024 10M sh
Operating Cash Flow Q2 2026 · Sep 30, 2025 −$244.02K
Operating Cash Flow Q2 2026 · Sep 30, 2024 $753.12K
Cash And Equivalents Q2 2026 · Sep 30, 2025 $190.91K
Cash And Equivalents Q2 2026 · Mar 31, 2025 $748.72K
Stockholders Equity Q2 2026 · Sep 30, 2025 $5.14M
Stockholders Equity Q2 2026 · Mar 31, 2025 $4.99M
Stockholders Equity Q2 2026 · Sep 30, 2024 $5.35M
Stockholders Equity Q2 2026 · Mar 31, 2024 $4.25M
Current Liabilities Q2 2026 · Sep 30, 2025 $3.03M
Current Liabilities Q2 2026 · Mar 31, 2025 $2.92M
Total Liabilities Q2 2026 · Sep 30, 2025 $4.49M
Total Liabilities Q2 2026 · Mar 31, 2025 $4.43M
Current Assets Q2 2026 · Sep 30, 2025 $8.86M
Current Assets Q2 2026 · Mar 31, 2025 $8.73M
Total Assets Q2 2026 · Sep 30, 2025 $9.63M
Total Assets Q2 2026 · Mar 31, 2025 $9.42M
Eps Diluted Q2 2026 · Sep 30, 2025 $0.01
Eps Diluted Q2 2026 · Sep 30, 2024 $0.08
Eps Basic Q2 2026 · Sep 30, 2025 $0.01
Eps Basic Q2 2026 · Sep 30, 2024 $0.08
Sga Expense Q2 2026 · Sep 30, 2025 $724.62K
Sga Expense Q2 2026 · Sep 30, 2024 $881.12K
Net Income Q2 2026 · Sep 30, 2025 $153.74K
Net Income Q2 2026 · Sep 30, 2024 $828.56K
Operating Income Q2 2026 · Sep 30, 2025 −$701.75K
Operating Income Q2 2026 · Sep 30, 2024 −$879.37K
Gross Profit Q2 2026 · Sep 30, 2025 $930.76K
Gross Profit Q2 2026 · Sep 30, 2024 $1.91M
Cost Of Revenue Q2 2026 · Sep 30, 2025 $6.21M
Cost Of Revenue Q2 2026 · Sep 30, 2024 $9.19M
Revenue Q2 2026 · Sep 30, 2025 $7.14M
Revenue Q2 2026 · Sep 30, 2024 $11.09M